查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678693

全球血液生物標記市場：市場規模、佔有率、趨勢分析（按類型、應用、技術、最終用途和地區）、細分市場預測（2025-2030 年）

Blood Based Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers), By Application (Cancer), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血液生物標記市場的成長與趨勢：

根據 Grand View Research 的新報告，全球血液生物標記市場預計到 2030 年將達到 115.8 億美元。

預計 2025 年至 2030 年期間，市場複合年成長率為 7.2%。慢性病盛行率的上升以及資金籌措將推動血液生物標記產業的發展。隨著對非侵入性診斷工具的需求不斷增加，政府、私人公司和研究機構正在優先資助針對多種疾病（包括癌症、心血管和神經系統疾病）的血液生物標記的開發和檢驗的研究。擴大投資將促進創新突破，提高生物標記的準確性和可靠性，並加速新診斷測試的商業化。此外，學術機構、生物技術公司和醫療保健提供者之間日益增多的合作將促進新技術的市場開發，進一步促進市場擴張和改善患者治療效果。

隨著高通量篩檢、次世代定序(NGS) 和質譜技術的創新提高了生物標記檢測的靈敏度和準確性，技術進步和產品發布正在極大地推動市場的發展。這些進步使得人們能夠識別以前無法檢測到的生物標記物，擴大了可透過血液檢查診斷的疾病範圍。此外，微流體設備和穿戴式感測器的發展使得測試速度更快、更具成本效益且侵入性更小。隨著技術的不斷進步，基於血液的生物標記檢測的可擴展性和臨床適用性不斷提高，使其更易於獲取，對於早期疾病檢測、個人化醫療和監測治療效果更有價值，從而推動市場成長。

Exact Sciences Corp. 公佈了基於血液的結腸癌篩檢測試的令人鼓舞的性能資料，凸顯了基於血液的生物標記領域的一項重大進步：早期檢測測試的有效性日益提高。該檢測對大腸直腸癌的敏感性為 88.3%，對晚期癌前病變的敏感性為 31.2%，特異性高達 90.1%，該檢測的成功證明了血液診斷在癌症篩檢方面的潛力日益成長。隨著越來越多創新的血液檢測表現出高準確性和可靠性，對這些非侵入性早期檢測解決方案的需求預計將激增，從而推動市場進一步發展。這些發展將刺激投資，改善患者的治療效果，並加強以血液為基礎的生物標記在多種癌症類型的應用。

血液生物標記市場：分析概述

  • 2024 年，基因生物標記部分成為血液生物標記產業中最大的收益部分。這是因為全面基因組分析的進步導致遺傳生物標記在血液診斷中的應用越來越廣泛。
  • 由於持續研究開發用於早期診斷的血液生物標記物，以及行業領導者之間的廣泛合作，癌症成為 2024 年最主要的領域。癌症患者數量的增加以及對非侵入性診斷方法的需求增加正在推動這一領域的成長。
  • 由於技術進步和專注於開發創新血液生物標記的主要企業的增加，次世代定序(NGS) 領域預計將在 2024 年佔據市場主導地位。
  • 2024 年，醫院和診所部門佔據了最終用途部門的最大佔有率。這種主導地位是由於慢性病的盛行率不斷上升。醫院是所有先進診斷服務（如血液生物標記檢測）的中心，因此患者對老牌醫院更有信任，從而推動了市場成長。
  • 2024 年，北美將主導全球市場。先進診斷工具的採用率不斷提高、認知不斷提高、該地區行業領袖的存在以及監管部門的核准預計將促進市場成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 血液生物標記市場：促進因素、趨勢和範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 血液生物標記市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 血液生物標記市場：按類型分類的估計和趨勢分析

  • 全球血液生物標記市場：儀表板、按類型分類
  • 全球血液生物標記市場：變異分析（按類型）
  • 全球血液生物標記市場類型（以收益為準）
  • 基因生物標記
  • 蛋白質生物標記
  • 代謝生物標記
  • 基於細胞的生物標記
  • 表觀遺傳生物標記

第 5 章 血液生物標記市場：按應用分類的估計和趨勢分析

  • 全球血液生物標記市場：儀表板、按應用分類
  • 全球血液生物標記市場：變異分析（按應用）
  • 全球血液生物標記市場應用情況（以收益為準）
  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 免疫系統疾病
  • 其他

6. 血液生物標記市場：按最終用途分類的估計和趨勢分析

  • 全球血液生物標記市場：儀表板、依最終用途分類
  • 全球血液生物標記市場：變異分析（依最終用途）
  • 全球血液生物標記市場按最終用途分類（以收益為準）
  • 醫院和診所
  • 診斷實驗室
  • 研究和學術機構
  • 其他

第7章血液生物標記市場：區域估計和趨勢分析（按類型、應用、技術和最終用途）

  • 區域控制面板
  • 血液生物標記市場：各地區差異分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Abbott
    • BIOMERIEUX
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc
    • Cleveland Diagnostics, Inc.
    • Sysmex Corporation
Product Code: GVR-4-68040-519-1

Blood Based Biomarkers Market Growth & Trends:

The global blood based biomarkers market size is expected to reach USD 11.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.

Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.

The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.

Blood Based Biomarkers Market Report Highlights:

  • In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.
  • Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment's growth.
  • Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.
  • Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.
  • The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type, application, technology, and end-use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Advancements in biomarker technology
      • 3.2.1.3. Expanding research and funding support
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High development and validation costs
      • 3.2.2.2. Lack of reimbursement policies for biomarker treatment
  • 3.3. Blood Based Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Environmental landscape

Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood Based Biomarkers Market: Type Dashboard
  • 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
  • 4.3. Global Blood Based Biomarkers Market by Type, Revenue
  • 4.4. Genetic Biomarkers
    • 4.4.1. Genetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Protein Biomarkers
    • 4.5.1. Protein Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Metabolic Biomarkers
    • 4.6.1. Metabolic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Cell-Based Biomarkers
    • 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Epigenetic Biomarkers
    • 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis

  • 5.1. Global Blood Based Biomarkers Market: Application Dashboard
  • 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
  • 5.3. Global Blood Based Biomarkers Market by Application , Revenue
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Neurological Diseases
    • 5.6.1. Neurological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Immunological Diseases
    • 5.7.1. Immunological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Global Blood Based Biomarkers Market: End Use Dashboard
  • 6.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
  • 6.3. Global Blood Based Biomarkers Market by End Use, Revenue
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Research & Academic Institutes
    • 6.6.1. 6.6. Research & academic institutes market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Abbott
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. BIOMERIEUX
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Thermo Fisher Scientific, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bio-Rad Laboratories, Inc
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Cleveland Diagnostics, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Sysmex Corporation
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 4 Global Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 5 Global Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 6 Global Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 7 Global Blood Based Biomarkers, by Region, 2018 - 2030 (USD Billion)
  • Table 8 North America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 9 North America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 10 North America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 11 North America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 12 North America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 16 U.S. Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 17 Canada Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 18 Canada Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 19 Canada Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 20 Canada Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 21 Mexico Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 22 Mexico Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 23 Mexico Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 24 Mexico Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 25 Europe Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 26 Europe Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 27 Europe Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 28 Europe Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 29 Europe Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 30 Germany Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 31 Germany Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 32 Germany Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 33 Germany Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 34 UK Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 35 UK Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 36 UK Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 37 UK Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 38 France Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 39 France Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 40 France Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 41 France Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 42 Italy Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 43 Italy Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 44 Italy Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 45 Italy Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 46 Spain Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 47 Spain Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 48 Spain Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 49 Spain Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 50 Denmark Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 51 Denmark Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 52 Denmark Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 53 Denmark Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 54 Sweden Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 55 Sweden Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 56 Sweden Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 57 Sweden Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 58 Norway Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 59 Norway Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 60 Norway Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 61 Norway Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 62 Asia Pacific Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 67 China Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 68 China Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 69 China Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 70 China Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 71 Japan Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 72 Japan Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 73 Japan Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 74 Japan Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 75 India Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 76 India Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 77 India Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 78 India Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 79 South Korea Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 80 South Korea Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 81 South Korea Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 82 South Korea Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 83 Australia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 84 Australia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 85 Australia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 86 Australia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 87 Thailand Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 88 Thailand Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 89 Thailand Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 90 Thailand Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 91 Latin America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 92 Latin America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 93 Latin America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 94 Latin America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 95 Latin America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 96 Brazil Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 97 Brazil Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 98 Brazil Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 99 Brazil Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 100 Argentina Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 101 Argentina Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 102 Argentina Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 103 Argentina Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 104 Middle East & Africa Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East & Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East & Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 107 Middle East & Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 108 Middle East & Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 109 South Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 110 South Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 111 South Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 112 South Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 117 UAE Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 118 UAE Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 119 UAE Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 120 UAE Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Blood Based Biomarkers Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Blood Based Biomarkers Market: Type Movement Analysis
  • Fig. 16 Global Blood Based Biomarkers Market, for Genetic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 17 Global Blood Based Biomarkers Market, for Protein Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Blood Based Biomarkers Market, for Metabolic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 19 Global Blood Based Biomarkers Market, for Cell-Based Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 20 Global Blood Based Biomarkers Market, for Epigenetic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Blood Based Biomarkers Market, for Application, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Blood Based Biomarkers Market, for Cancer, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Blood Based Biomarkers Market, for Cardiovascular Diseases, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Blood Based Biomarkers Market, for Neurological Diseases, 2018 - 2030 (USD Billion)
  • Fig. 25 Global Blood Based Biomarkers Market, for Immunological Diseases, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 27 Global Blood Based Biomarkers Market, for Technology, 2018 - 2030 (USD Billion)
  • Fig. 28 Global Blood Based Biomarkers Market, for Next-Generation Sequencing, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Blood Based Biomarkers Market, for Polymerase Chain Reaction, 2018 - 2030 (USD Billion)
  • Fig. 30 Global Blood Based Biomarkers Market, for Immunoassays, 2018 - 2030 (USD Billion)
  • Fig. 31 Global Blood Based Biomarkers Market, for Mass Spectrometry, 2018 - 2030 (USD Billion)
  • Fig. 32 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 33 Global Blood Based Biomarkers Market: End Use Movement Analysis
  • Fig. 34 Global Blood Based Biomarkers Market, for Hospitals & Clinics, 2018 - 2030 (USD Billion)
  • Fig. 35 Global Blood Based Biomarkers Market, for Diagnostic Laboratories, 2018 - 2030 (USD Billion)
  • Fig. 36 Global Blood Based Biomarkers Market, for Research & Academic Institutes, 2018 - 2030 (USD Billion)
  • Fig. 37 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 Regional Outlook, 2024 & 2030
  • Fig. 40 Global Blood Based Biomarkers Market: Region Movement Analysis
  • Fig. 41 North America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 42 U.S. Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 43 Canada Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Mexico Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Europe Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 46 Germany Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 47 UK Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 48 France Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Italy Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Spain Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 51 Denmark Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 52 Sweden Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Norway Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 54 Asia Pacific Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 55 Japan Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 56 China Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 57 India Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Australia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 59 South Korea Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Thailand Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 61 Latin America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Brazil Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 63 Argentina Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Middle East and Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 65 South Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 66 Saudi Arabia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 67 UAE Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 68 Kuwait Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)